Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: Compugen Ltd. (CGEN) Report Updated: Oct 15, 2017 | Print This Page

Get more stock ratings by Louis Navellier

Compugen Ltd. (CGEN)

Rating: Sell Volatility: Moderate
Total Grade: D Industry: Life Sciences Tools & Services
Competitors: MTD,A,CBMX,PRAH

Stock Analysis

Rating: Monthly View

October November December January February March April May June July August September

Rating: Weekly View

This Week: D down no change
Last Week: D same no change
Two Weeks Ago: D up upgrade
service keys

Compugen Ltd.© quotemedia

Company Profile

Compugen Ltd., a drug discovery company, engages in the research, development, and commercialization of therapeutic and product candidates primarily in the United States, Europe, and Israel. It primarily focuses on the discovery and development of monoclonal antibodies (mAbs) and therapeutic proteins to address the unmet needs in the fields of oncology and immunology. The company’s therapeutic proteins pipeline includes CGEN-15001, CGEN-15021, CGEN-15091, CGEN-15031, and CGEN-15051 for the treatment of a range of diseases including cancer, autoimmune and infectious diseases, blood-related disorders, and others. Its monoclonal antibody therapy product candidates comprise CGEN-15001T, CGEN-15022, CGEN-15049, CGEN-15027, CGEN-15092, and CGEN-15052. The company was incorporated in 1993 and is headquartered in Tel Aviv, Israel.